Abstract
Many cancer therapeutics, including radiation therapy, damage DNA eliciting the DNA damage response (DDR). Clinical assays that characterise the DDR could be used to personalise cancer treatment by indicating the extent of damage to tumour and normal tissues and the nature of the cellular response to that damage. The phosphorylated histone γH2AX is generated early in the response to DNA double-strand breaks, the most deleterious form of DNA damage. Translational researchers are developing tissue sampling and assay strategies to apply the measurement of γH2AX to a range of clinical questions, including that of tumour response. The presence of γH2AX is also associated with other cell states including replication stress, hypoxia and apoptosis, which could influence the relationship between γH2AX and clinical endpoints. This review aims to assess the potential of γH2AX as a practical and clinically useful biomarker of tumour and normal tissue responses to therapy.
Keywords: Biomarker, cancer, double-strand break, γH2AX, radiotherapy.
Current Molecular Medicine
Title:Can γH2AX be Used to Personalise Cancer Treatment?
Volume: 13 Issue: 10
Author(s): K. Shah, B. Cornelissen, A. E. Kiltie and K. A. Vallis
Affiliation:
Keywords: Biomarker, cancer, double-strand break, γH2AX, radiotherapy.
Abstract: Many cancer therapeutics, including radiation therapy, damage DNA eliciting the DNA damage response (DDR). Clinical assays that characterise the DDR could be used to personalise cancer treatment by indicating the extent of damage to tumour and normal tissues and the nature of the cellular response to that damage. The phosphorylated histone γH2AX is generated early in the response to DNA double-strand breaks, the most deleterious form of DNA damage. Translational researchers are developing tissue sampling and assay strategies to apply the measurement of γH2AX to a range of clinical questions, including that of tumour response. The presence of γH2AX is also associated with other cell states including replication stress, hypoxia and apoptosis, which could influence the relationship between γH2AX and clinical endpoints. This review aims to assess the potential of γH2AX as a practical and clinically useful biomarker of tumour and normal tissue responses to therapy.
Export Options
About this article
Cite this article as:
Shah K., Cornelissen B., Kiltie E. A. and Vallis A. K., Can γH2AX be Used to Personalise Cancer Treatment?, Current Molecular Medicine 2013; 13 (10) . https://dx.doi.org/10.2174/1566524013666131111124531
DOI https://dx.doi.org/10.2174/1566524013666131111124531 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorogold Induces Persistent Neurological Deficits and Circling Behavior in Mice Over-Expressing Human Mutant Tau
Current Neurovascular Research Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Effect of Oil Extract from Microalgae (<i>Schizochytrium</i> sp.) on the Viability and Apoptosis of Human Osteosarcoma Cells
Current Pharmaceutical Biotechnology The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue Presenting as Multiple Pulmonary Lesions: Case Report and Review of the Literature
Current Respiratory Medicine Reviews Green Synthesis of Zinc Oxide Nanoparticles (ZnO NPs) using Aqueous Extract of <i>Tagetes Erecta</i> flower and Evaluation of its Antioxidant, Antimicrobial, and Cytotoxic activities on HeLa cell line.
Current Biotechnology How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Wheel of Fortune – Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics
Current Chemical Biology Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Role of CHK2 Inhibitors in the Cellular Responses to Ionizing Radiation
Mini-Reviews in Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Anti-Cancer / Anti-Tumor
Current Bioactive Compounds